|
Pneumothorax
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Comparisons of the gene expression profiles of CECs in pneumothorax (CECs-SP group) with CECs in pelvic endometriosis (CECs-non-SP group) have revealed significantly higher expression of HER2 in the CECs-SP group compared with the CECs-non-SP group.
|
31542450 |
2020 |
|
Spontaneous pneumothorax
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Comparisons of the gene expression profiles of CECs in pneumothorax (CECs-SP group) with CECs in pelvic endometriosis (CECs-non-SP group) have revealed significantly higher expression of HER2 in the CECs-SP group compared with the CECs-non-SP group.
|
31542450 |
2020 |
|
Endometriosis of pelvis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Comparisons of the gene expression profiles of CECs in pneumothorax (CECs-SP group) with CECs in pelvic endometriosis (CECs-non-SP group) have revealed significantly higher expression of HER2 in the CECs-SP group compared with the CECs-non-SP group.
|
31542450 |
2020 |
|
Lipid-Rich Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report a case of lipid-rich breast carcinoma which showed hormone receptor positivity and Her-2 Neu negative.
|
31603128 |
2020 |
|
Mixed carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
All HER2-positive carcinosarcomas had either a serous or a mixed carcinoma component, and all but one HER2-positive tumors were of uterine primaries.
|
31477811 |
2020 |
|
Dyspnea
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Here we report a case of Takotsubo cardiomyopathy associated with the use of dual anti-HER2 therapy in a 63-year-old woman who presented to the emergency department with an 8- to 10-hour history of progressive dyspnea after completing her third cycle of pertuzumab plus trastuzumab in addition to nab-paclitaxel chemotherapy.
|
30389744 |
2019 |
|
Epidermodysplasia Verruciformis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using a machine learning algorithm to EV signature based on their size and marker expression, we demonstrate that the isolated microvesicles are more efficient than exosomes and apoptotic bodies in discriminating breast cell lines and Stage II breast cancer patients with varied immunohistochemical expression of HER2.
|
30789261 |
2019 |
|
Fatigue
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
HER2 vaccines are well tolerated with increased AR of fatigue, injection site reactions, and fever/chills/rigors.
|
30679903 |
2019 |
|
Mucocutaneous Lymph Node Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Third, we found that HER2 KD significantly attenuated the tumorigenicity of ovarian cancer cells.
|
30314995 |
2019 |
|
Myocardial Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
The primary endpoint was completion of the planned HER2-targeted therapies without developing either a cardiac event (CE) defined as HF, myocardial infarction, arrhythmia or cardiac death or significant asymptomatic worsening of LVEF.
|
30852761 |
2019 |
|
Obesity, Morbid
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using model 2, an association was identified between an advanced disease stage and 2 factors: morbid obesity (OR, 1.9; P = .02) and positive human epidermal growth factor receptor 2 (OR, 1.8; P = .045).
|
30236925 |
2019 |
|
Osteopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, inhibiting ErbB1 and ErbB2 by lapatinib or blocking cell division by paclitaxel or their combination causes significant trabecular bone loss and bone marrow adiposity involving a switch in osteogenesis/adipogenesis potential, altered expression of some major molecules of the Wnt/β-catenin signalling pathway, and increased recruitment of bone-resorbing osteoclasts.
|
30260048 |
2019 |
|
Parotid Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Post-superficial parotidectomy pathology revealed the parotid gland tumour to be oestrogen receptor-positive and HER2 receptor-positive, thus ruling out the initial differential diagnosis of a pleomorphic adenoma.
|
31594782 |
2019 |
|
Dermatologic disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Metastatic Dermatosis in Breast Carcinoma on Adjuvant Trastuzumab: Is Skin a Sanctuary Site in Human Epidermal Growth Factor Receptor-2-Amplified Disease?
|
30210167 |
2019 |
|
Ovarian Hyperstimulation Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study demonstrated that granulosa cell-secreted AREG plays an important role in the development of OHSS, suggesting that the EGFR/HER2-mediated signaling could be a novel drug target for the prevention and treatment of OHSS.
|
31167229 |
2019 |
|
Renal fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In vivo, the ectopic expression of HER2 in these cells was sufficient to activate the interstitial fibroblast and initiate interstitial fibrosis, whereas inhibiting HER2 reduced the accumulation of myofibroblasts and the extent of renal fibrosis in the mouse obstruction model and in streptozotocin (STZ)-induced diabetic mice.
|
31327474 |
2019 |
|
Inverted Papilloma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ErbB1 and ErbB2 overexpression in patients with sinonasal inverted papilloma and inverted papilloma with squamous cell carcinoma in China.
|
31556771 |
2019 |
|
Uveal melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
|
30622115 |
2019 |
|
Stage II Colon Cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We analyzed HER2 mRNA expression of 206 patients in GSE39582 dataset and explored the impact of HER2 expression on benefit from adjuvant chemotherapy for stage II colon cancer patients.
|
30420187 |
2019 |
|
Osteosarcoma recurrent
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HER2 overexpression in OS is not generally associated with gene amplification, with low-level expression regarded as HER2 "negative", as per criteria used to classify breast cancer HER2 status.
|
31491952 |
2019 |
|
Laryngeal squamous cell carcinoma recurrent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Persistent/recurrent LSCC was characterized by a high rate of inactivating alterations in TP53 (38.1%) and CDKN2A (33%), amplification events of CCND1 (19.1%), and ERBB2 (14.3%), and NOTCH1 (19.1%) mutations.
|
30548484 |
2019 |
|
Adenocarcinoma, intestinal type
|
0.010 |
Biomarker
|
disease |
BEFREE |
The present is the largest study of sinonasal ITAC tested with both IHC and CISH confirmation for HER2 status.
|
31047725 |
2019 |
|
Adenocarcinoid tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein we report a rare case of a 60-year-old male patient suffering from MANEC of the gastroesophageal junction with HER2/neu overexpression who developed severe orbital and ocular neurotoxicity (grade 3 according to CTCAE v4.03) after intravenous cisplatin.
|
30799422 |
2019 |
|
Parathyroid Gland Adenocarcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Nine PC samples (47%) harbored at least one potentially actionable genomic alteration including in the after genes: ROS1 (5/19; 26%), PTEN (3/19; 16%), TSC1 (2/19; 11%), PIK3CA (1/19; 5%), AKT1 (1/19; 5%), MTOR (1/19; 5%), ERBB2 (1/19; 5%), NTRK1 (1/19; 5%), IDH1 (1/19; 5%) and FGFR3 (1/19; 5%).
|
30362515 |
2019 |
|
Inflammatory carcinoma of breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to analyze the association of hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) based breast cancer subtypes in stage IV inflammatory breast cancer (IBC) with preferential site of distant metastases and overall survival (OS).
|
31623649 |
2019 |